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Background: Recommendations for secondary hyperparathyroidism (SHPT) consider that a “one-size-fits-all” target
enables efficacy of care. In routine clinical practice, SHPT continues to pose diagnosis and treatment challenges.
One hypothesis that could explain these difficulties is that dialysis population with SHPT is not homogeneous.
Methods: EPHEYL is a prospective, multicenter, pharmacoepidemiological study including chronic dialysis patients
(≥3 months) with newly SHPT diagnosis, i.e. parathyroid hormone (PTH) ≥500 ng/L for the first time, or initiation
of cinacalcet, or parathyroidectomy. Multiple correspondence analysis and ascendant hierarchical clustering on
clinico-biological (symptoms, PTH, plasma phosphorus and alkaline phosphatase) and treatment of SHPT (cinacalcet,
vitamin D, calcium, or calcium-free calcic phosphate binder) were performed to identify distinct phenotypes.
Results: 305 patients (261 with incident PTH ≥ 500 ng/L; 44 with cinacalcet initiation) were included. Their mean
age was 67 ± 15 years, and 60% were men, 92% on hemodialysis and 8% on peritoneal dialysis. Four subgroups of
SHPT patients were identified: 1/ “intermediate” phenotype with hyperphosphatemia without hypocalcemia
(n = 113); 2/ younger patients with severe comorbidities, hyperphosphatemia and hypocalcemia, despite SHPT
multiple medical treatments, suggesting poor adherence (n = 73); 3/ elderly patients with few cardiovascular
comorbidities, controlled phospho-calcium balance, higher PTH, and few treatments (n = 75); 4/ patients who
initiated cinacalcet (n = 43). The quality criterion of the model had a cut-off of 14 (>2), suggesting a relevant
classification.
Conclusion: In real life, dialysis patients with newly diagnosed SHPT constitute a very heterogeneous population.
A “one-size-fits-all” target approach is probably not appropriate. Therapeutic management needs to be adjusted to
the 4 different phenotypes.
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In the 70’s, secondary hyperparathyroidism (SHPT) was
described as a severe bone disease occurring in young
end-stage renal disease (ESRD) patients with significant
duration of dialysis. When parathyroid hormone (PTH)
was very high, up to 1000 ng/L, associated with hyper-
calcemia, the only treatment was subtotal parathyroïdec-
tomy [1,2]. In the 90’s, access to kidney transplantation
for the young and dialysis for the old led to a rapid age-
ing of dialyzed population [3]. During the first decade of
the millennium, a new paradigm emerged. First, SHPT
was considered not only as a bone disease, but also as a
vascular disease [4]. Second, SHPT turned out to be a
biological rather than a clinical disease at bedside [5]. A
“one-size-fits-all” approach was recommended: PTH
under 300ng/L from 2003 to 2009 according to K-DOQI
[6]. Due to variability in PTH measurement, the target
was modified in 2009: “maintaining PTH levels in the
range of approximately two to nine times the upper nor-
mal limit for the assay” [7,8]. Third, cinacalcet tends to
be seen by the clinicians as the most appropriate solu-
tion for the treatment of SHPT due to its mechanism of
action, when conventional therapy is not effective
enough [6,9]. But the randomized controlled EVOLVE
study, published in 2012, failed to demonstrate efficacy
of cinacalcet to reduce the risk of death or major cardio-
vascular events [10]. Today, the exact importance of
PTH is still debated [11].
Large observational cross-sectional studies about SHPT
have recently been published [12-15]. An incidence/preva-
lence bias may have hampered a precise description of
SHPT phenotypes [16]. In order to capture the pheno-
types of SHPT at bedside, we meticulously enrolled all dia-
lysis patients of the REIN registry - Region of Lorraine
with newly marked PTH elevation in a prospective obser-
vational study from December 2009 to May 2012. At in-
clusion, we delivered a validated questionnaire to measure
clinical symptoms. With an original statistical analysis, we
demonstrated that high PTH levels matched with 4 very
different phenotype profiles, suggesting that a “one-size-
fits-all” target approach for SHPT was not appropriate.
Methods
The pharmacoepidemiological EPHEYL (Étude PHarma-
coÉpidémiologique de l’hYperparathyroïdie secondaire
en Lorraine) study is a 2-year, open-cohort, prospective,
observational study on incident SHPT, i.e. newly diag-
nosed, with a 2-year follow-up, set in the 12 dialysis
units located in the French region of Lorraine (public or
private).
Inclusion criteria
Adult patients included in EPHEYL were on dialysis
(hemodialysis or peritoneal dialysis) for at least 3 monthswith one of the following criteria: for the first time 1)
PTH ≥ 500ng/L, 2) initiation of cinacalcet, 3) parathy-
roidectomy if severe SHPT. The PTH cut-off value of
500 ng/L was chosen at the time of 2003 K-DOQI [6].
Indeed, when we initiated the study, the updated KDIGO
recommendations were not effective, and PTH levels
between 150 and 300 ng/L were advocated [6,8]. The indi-
cation for parathyroidectomy or the use of a calcimimetic
were retained when PTH level was ≥ 500 ng/L, hence the
choice of this threshold in our study.
From 1st December, 2009 to 31st May, 2012, all patients
who were on dialysis for at least 3 months were identified
through the REIN registry - Region of Lorraine [17]. The
occurrence of one out of the three inclusion criteria was
prospectively followed up in all these patients.
Patients were included in the study at the time of PTH
dosing, initiation of cinacalcet, or parathyroidectomy.
Physicians were encouraged to adhere to the KDIGO™
guidelines updated in 2009 [8].
Data collection
The following socio-demographic and clinical data were
retrieved from the REIN registry: age, gender, body mass
index (BMI), type of dialysis, dialysis vintage, primary eti-
ology of nephropathy, comorbidities (smoking, diabetes,
cardiovascular diseases, hypertension, respiratory diseases
and cancer), and being on renal transplant waiting list
[17]. The vast majority of patients were Caucasians.
BMI was described as a continuous quantitative variable
and obesity (BMI >30 kg/m2) as a binary variable. Primary
etiology of nephropathy was classified into diabetic
nephropathy, vascular nephropathy, glomerulonephritis,
pyelonephritis, hereditary nephropathy, and other/unknown.
Cardiovascular diseases comprised history of heart failure,
cardiac heart disease, acute coronary syndrome, arrhythmia,
peripheral arterial disease, and stroke. Respiratory diseases
encompassed history of chronic respiratory insufficiency,
asthma, and obstructive pulmonary disease. Hypertension
was considered present if: diastolic and/or systolic blood
pressure greater than 80 and 130 mm Hg, respectively, or a
current antihypertensive therapy.
SHPT symptoms experienced by patients were assessed
by using: 1) the Parathyroidectomy Assessment of Symp-
toms (PAS) questionnaire. This self-administered ques-
tionnaire validated in dialysis patients with SHPT assessed
the severity of 14 SHPT symptoms (Table 1) experienced
by patients using a visual analog scale (VAS) which ranged
from 0 (not experiencing any symptom) to 100 (experien-
cing the most extreme aspect of the symptom) [18-20].
This questionnaire was administered at the time of inclu-
sion. PAS scores were analyzed as quantitative variables or
proportion of patients with at least one symptom scoring
more than 0; 2) the collection of clinical signs reported in
medical records such as osteoarticular pain, myasthenia,
Table 1 Specific symptoms assessed by the
parathyroidectomy assessment of symptoms (PAS)
questionnaire, a self-administered disease-specific
outcome tool, in patients with secondary
hyperparathyroidism (SHPT)
Items in PAS questionnaire
1. Pain in the bones
2. Feeling tired easily
3. Mood swings
4. Feeling “blue” or depressed
5. Pain in the abdomen
6. Feeling weak
7. Feeling irritable
8. Pain in the joints
9. Forgetfulness
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http://www.biomedcentral.com/1471-2369/15/132bone fractures, paresthesia, pruritus, tetany, and calci-
phylaxis. A patient was symptomatic if at least one
symptom had a PAS score greater than 0 or was
reported in his medical records.
The following biological parameters were collected at
the time of inclusion: PTH, calcemia, phosphorus, vitamin
D, alkaline phosphatase (ALP), albumin, hemoglobin and
measured ionized calcium. KDIGO™ guidelines have re-
commended to maintain PTH up to 2 to 9-fold above the
normal range [8]. PTH was therefore described as binary
variable (in or out of target) and quantitative variable
(multiple of upper normal limit). According to KDIGO™
guidelines, calcemia was checked as hypo-, normo- or
hypercalcemia using 2.1 and 2.6 mmol/L as cut-off values;
phosphatemia as hypo-, normo- et hyperphosphatemia
using 0.8 and 1,45 mmol/L as cut-off values. ALP was
analyzed according to 2 stages using medians as cut-off
values, albuminuria according to 2 stages using 25 g/L as
cut-off value, and hemoglobin according to 3 stages using
10 and 12 g/dL as cut-off values.
Four technologies were used for PTH dosing: chemilu-
minometric technology (48%), electro cheminulometric
method (23%), immuno-enzymology (11%), immune
chemiluminometric technology (16%), and unknown (2%);
each kit was provided by several laboratories which had
different standards.
All drugs acting on phospho-calcic metabolism were
collected and classified into 4 groups: vitamin D and
analogs, calcium supplementation, calcium-free phosphorus
binders, and cinacalcet.A standardized form was used to collect data from
medical records. A Steering Committee consisting of an
epidemiologist (CLA) and a nephrologist (LF) reviewed
all forms and medical records when collected biological
data were out of international standards.Ethics statement
This study was conducted in compliance with French
regulations concerning pharmaco-epidemiological
studies [21]. Approvals from the French data protection
agency (CNIL: n° 904163) and from the Advisory
Committee on information processing research in the
field of health located in the region of Lorraine
(CCTIRS: n° 0428) were obtained through the national
REIN registry. An information sheet was displayed in all
dialysis units, and each patient was given an individual
written information sheet at the initiation of dialysis.Statistical analyses
Patient characteristics were described as proportions for
categorical variables, and means and standard devia-
tions (SD) for continuous variables, except PAS scores
described as medians.
Multivariate analyses using multiple correspondence
analysis (MCA) and ascendant hierarchical clustering on
clinical, biological and therapeutic characteristics of
SHPT were performed to identify subgroups of patients
[22]. All these parameters were binary variables.
MCA was applied to determine the major axes
summarizing more clearly data [22]. This method gives a
set of coordinates of the categories of variables, and
thus reveals the relationships between the individuals
and the different categories. Each principal component
was interpreted in terms of amount of contribution for
each category to variance of axis. The contribution of a
variable was statistically significant when its mean was
greater than 1/p, (p = number of categories of variables).
Graphical evaluation was built using the major compo-
nents in a series of two-dimensional graphs.
Then an ascendant hierarchical clustering was used
to determine the number of subgroups on the basis of
coordinates of the main components retained by MCA.
The 4 clustered subgroups were numbered according to
the order of the selection for the classification. The
validity of this method was measured by the “cubic
clustering criterion” with a cut-off of 2. After subgroups
were selected, χ2 tests were performed to compare and
highlight parameters defining each distinct profile of
patients.
The statistical analyses were performed using SAS
software, version 9.2 (SAS Institute, North Carolina,
US).
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Patients
A total of 2137 patients who were on dialysis for at least
3 months, with PTH < 500 ng/L were retrieved from the
REIN registry – Region of Lorraine between 1st December,
2009 and 31st May, 2012. Among them, 305 patients
were included in the EPHEYL study: 86% with an
incident PTH ≥500 ng/L (n = 261), 14% with an initi-
ation of cinacalcet (n = 44), and 0% with a first-line
parathyroidectomy (Figure 1).
There was no statistically significant difference in
socio-demographic and clinical characteristics between
both groups according to inclusion criteria (Table 2).
Regarding PTH levels, 10 different values for the upper
normal limit were obtained, and ranged from 38.8 to
638 ng/L (median value: 560 ng/L). Despite these high
values PTH remained in the KDIGO™ target range in
64% of patients.
The distribution of PTH according to multiples of the
upper normal limit revealed that 60% of patients main-
tained PTH up to 8-fold above the upper normal limit
(Figure 2).Dialysis patients 
- For at least 3 months 
- PTHa < 500 ng/L 
[REIN registry – region of Lorr
From 1
st





PTH ≥ 500 ng/L (N=261)
Cinacalcet (N=44)
Eligible on 31st, May 201
(N=823)
Figure 1 Disposition of patients. aParathyroid hormone.Among the 44 patients treated with cinacalcet, 36
patients had PTH within the KDIGO™ target range before
initiating the treatment. At 3 months of inclusion,
19 patients (43%) discontinued treatment with cinacalcet.
Cluster analysis
Ascendant hierarchical clustering identified four sub-
groups of patients according to their SHPT profiles as
shown Figure 3. The “cubic clustering criterion” of the
model was 14, higher than the cut-off of 2, validating the
classification.
The four clustered subgroups of patients were named
according to their main characteristics regarding vari-
ables used (Table 3) or not used for clustering patients
(Table 4):
– “Intermediate” patients (Group 1, 37%): patients
with hyperphosphatemia without hypocalcemia,
sharing similar characteristics with the next group
of patients (Group 2) but better controlled
– Younger patients with severe cardiovascular






Dialysis out of Lorraine (N=32)
Cinacalcet in the first 3 months
of dialysis (N=48)
History of parathyroidectomy (N=54)
Previous cinacalcet treatment before 
dialysis (N=56)
History of PTH ≥ 500 ng/L (N=157)
Other reasons (N=6)
2 
Table 2 Socio-demographic, clinical and biological characteristics for the EPHEYL population according to inclusion
criteria
Inclusion criteria
Study population Cinacalcet PTHa ≥ 500 ng/L
(N = 305) (N = 44, 14.4%) (N = 261, 85.6%)
Variables N N N p
Ageb, years 305 66.6 ± 15.3 44 63.3 ± 14.2 261 67.1 ± 15.4 0.122
Gender (males), % 305 60 44 71 261 58 0.126
BMIc,b, kg/m2 301 28.6 ± 6.9 44 28.3 ± 6.3 257 28.7 ± 7.1 0.697
>30 kg/m2, % 301 33.8 44 29.5 257 34.5 0.522
Type of dialysis, % 304 44 261 0.340
Hemodialysis 91.8 95.5 91.2
Peritoneal dialysis 8.2 4.5 8.8
Dialysis vintageb, months 305 27.5 ± 34.5 44 23.1 ± 24.5 261 28.3 ± 35.9 0.362
On transplant waiting list, % 300 44 256 0.636
Yes 8.3 11.4 7.9
No 91.7 88.6 92.1
Primary etiology of nephropathy, % 300 43 257 0.211
Diabetic nephropathy 16.0 23.3 14.8
Vascular nephropathy 16.3 20.9 15.6
Glomerulonephritis 10 11.6 9.7
Pyelonephritis 4.7 7.0 4.3
Hereditary nephropathy 7.7 11.6 7.0
Others/Unknown 45.3 36.2 48.7
Comorbidities, % 305 44 261
Cardiovascular diseases 49.5 45.5 50.2 0.561
Diabetes 44.9 31.8 47.1 0.590
Respiratory diseases 11.5 15.9 10.7 0.319
Cancer 13.1 6.8 14.2 0.181
Hypertension 85.9 88.6 85.4 0.573
Smoking 13.4 13.6 13.4 0.675
Clinical signs, % 305 44 261
Reported in medical records 27.2 31.8 26.4 0.458
Reporded in PASd questionnaire 44.9 31.8 47.1 0.059
Pain in the bonese 125 17 12 6 110 21 0.317
Feeling tired easilye 131 47 13 50 115 46 0.054
Mood swingse 124 23 13 20 108 23 0.216
Feeling “blue” or depressede 123 6 12 6 108 6 0.184
Pain in the abdomene 124 12 11 4 110 13 0.055
Feeling weake 126 48 12 23 111 49 0.067
Feeling irritablee 123 20 12 21 108 20 0.081
Pain in the jointse 128 40 13 52 112 39 0.130
Forgetfulnesse 126 12 14 12 109 12 0.317
Difficulty to stand upe 121 18 10 6 108 20 0.020
Headachee 115 5 11 13 101 5 0.372
Dry skine 122 35 13 49 106 30 0.325
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Table 2 Socio-demographic, clinical and biological characteristics for the EPHEYL population according to inclusion
criteria (Continued)
Being thirstye 121 51 13 51 105 51 0.265
Prurituse 122 20 12 49 107 16 0.302
Symptomatic patients, % 122 58 12 52.3 107 59 0.402
Biological parameters
PTHa,b, ng/L 305 619 ± 226 44 468 ± 262 261 644 ± 210 <0.0001
within KDIGO targetf, % 305 64.3 44 81.8 261 61.3 0.009
Serum calciumb, mg/L 305 87.0 ± 7.1 44 81.8 ± 7.1 261 87.1 ± 7.2 0.681
Calcemia, % 305 44 0.935
≤ 84 mg/L 42.6 43.2 42.5
84-104 mg/L 57.4 56.8 57.5
> 104 mg/L 0 0 261 0
Serum phosphorusb, mg/L 305 54.4 ± 16.5 44 50.9 ± 17.6 261 55.0 ± 16.3 0.129
Phosphatemia, % 305 44 0.675
<25 mg/L 2.6 2.3 2.7
25-45 mg/L 28.6 34.1 27.6
>45 mg/L 68.9 63.6 69.7
Serum alkaline phosphataseb, UI/L 299 103.4 ± 56.9 43 124.3 ± 97.0 256 99.9 ± 46.3 0.009
Bicarbonatemiab, mmol/L 303 22.2 ± 3.4 44 22.4 ± 2.8 258 22.1 ± 3.5 0.618
Albuminb, g/L 291 36.3 ± 4.6 42 36.7 ± 4.1 249 36.2 ± 4.6 0.504
Hemoglobinb, g/dL 279 10.3 ± 1.6 44 10.6 ± 1.5 235 10.3 ± 1.6 0.245
Vitamin Db, ng/mL 209 19.2 ± 13.5 31 15.8 ± 10.4 178 19.7 ± 13.9 0.138
Ionised calciumb, mmol/L 58 1.1 ± 0.2 3 0.9 ± 0.8 55 1.1 ± 0.1 0.031
Treatment, % 305 44 261
Vitamin D (per os) 63.9 72.7 62.5 0.189
Calcium 68.9 81.8 66.7 0.045
Phosphorus binders 59.3 61.4 59 0 0.768
Cinacalcet at inclusion 14.4 100 0 <0.0001
Cinacalcet at 3 months 27.2 56.8 22.2 <0.0001
aParathyroid hormone; bResults are presented as mean ± SD; cBody mass index; dParathyroidectomy Assessment of Symptoms; eMedian value; fThe 2009 updated
KDIGOTM (Kidney Disease: Improving Global Outcomes) guidelines have recommended target range for serum PTH to 2–9 times upper the normal range [8].
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mainly with hyperphosphatemia and hypocalcemia
despite multiple medical treatments, suggesting poor
adherence
– Elderly patients with a few cardiovascular
comorbidities (Group 3, 25%): rarely obese,
with longer dialysis vintage, mainly with
normophosphatemia and normocalcemia despite
few patients with SHPT treatment, with health
status appearing to be, at first, much better than
the one in group 2
– Patients who initiated cinacalcet (Group 4, 14%):
42 out of the 44 patients who initiated cinacalcet
and another patient were classified into a clearly
distinct subgroup (Figure 3). Two patients treated
with cinacalcet were classified into other groups.Discussion
EPHEYL is a well-characterized cohort of patients with
incident severe SHPT diagnosis described not only on
the basis of initiation of cinacalcet but also a cut-off
value for PTH [6]. An incident population helps to
accurately describe diseases, avoiding bias related to
incidence and prevalence mix [16]. We used an appro-
priate methodology, MCA and ascendant hierarchical
clustering, to identify homogeneous subgroups of cases
with a high statistical level validity [22]. Our four clus-
tered subgroups consisted of homogeneous patients with
same medical history, same prior therapy, and probably
similar characteristics concerning mineral bone diseases
and cardiovascular co-morbidities.
SHPT symptoms are difficult to assess due to the lack of
specificity. The self-administered questionnaire developed
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
40
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Figure 3 Identification of four distinct subgroups of dialysis patients with secondary hyperparathyroidism (SHPT) using multiple
correspondence analyses. The horizontal axis defined the presence or absence of calcium supplementation, the presence or absence of
treatment with cinacalcet, and serum PTH below or above 500 ng/L. The vertical axis defined a normophosphatemia, a hyperphosphatemia, the
absence or presence of phosphorus binders, high or low level of alkaline phosphatases, the presence or absence of vitamin D supplementation,
the presence or absence of calcium suplementation. Each patient is identified by a number and a color according to the following code: black
for group 1 (“intermediate”), green for group 2 (younger with severe cardiovascular comorbidities), blue for group 3 (elderly patients with few
cardiovascular comorbidities), pink for group 4 (“cinacalcet prescription”).
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Table 3 Characteristics of dialysis subgroups identified at time of secondary hyperparathyroidism (SHPT) diagnosis:
variables used to cluster dialysis patients at time of SHPT diagnosis
Variables Group 1a Group 2a Group 3a Group 4a
(N = 113, 37.2%) (N = 73, 24.0%) (N = 75, 24.7%) (N = 43, 14.1%) p
Clinical signs, %
All clinical signs 64 55 56 54 0.512
Clinical signs reported in PASb 55 45 37 33 0.031
Biological parameters
PTHc,d, ng/L 666 ± 182 630 ± 199 635 ± 233 449 ± 255 <0.0001
within KDIGO target, % 51 66 69 86 0.0004
Serum calciumd, mg/L 89 ± 7 82 ± 6 89 ± 6 87 ± 7 <0.0001
Hypocalcemia, % 29 81 27 42 <0.0001
Serum phosphorusd, mg/L 58 ± 17 62 ± 13 44 ± 12 52 ± 17 <0.0001
Hyperphosphatemia, % 81 96 25 67 <0.0001
Hypophosphatemia, % 4 4 0 2 <0.0001
Serum alkaline phosphatased, UI/L 100 ± 44 78 ± 29 120 ± 53 123 ± 99 <0.0001
Under median value, % 50 84 21 53 <0.0001
Treatments, %
Vitamin D and analogs 73 84 24 77 <0.0001
Calcium supplementation 68 95 35 86 <0.0001
Calcium-free phosphorus binders 58 93 25 65 <0.0001
Cinacalcet 0 0 3 98 <0.0001
aGroup 1: “intermediate” patients, Group 2: younger patients with severe comorbidities, Group 3: elderly patients with few cardiovascular comorbidities, Group 4:
patients who initiated cinacalcet; bParathyroidectomy Assessment of Symptoms questionnaire; cParathyroid hormone; dResults are presented as mean ± SD; p
corresponds to ANOVA.
Table 4 Characteristics of dialysis subgroups identified at time of secondary hyperparathyroidism (SHPT) diagnosis:
variables not used to cluster dialysis patients at time of SHPT diagnosis
Variables Group 1a Group 2a Group 3a Group 4a
(N = 113, 37.2%) (N = 73, 24%) (N = 75, 24.7%) (N = 43, 14.1%) p
Socio-demographic
Ageb, years 65 ± 17 66 ± 14 72 ± 13 63 ± 15 0.008
Gender (males), % 56 66 55 70 0.217
Dialysis
Type of dialysis, % 0.330
Hemodialysis 90 96 91 95
Peritoneal dialysis 10 4 9 5
Dialysis vintageb, months 27 ± 32 19 ± 22 38 ± 48 24 ± 24 0.007
Comorbidities, %
Cardiovascular diseases 48 62 41 47 0.086
Diabetes 46 55 41 30 0.070
BMIc, kg/m2 29 30 27 28 0.217
>30 kg/m2, % 37 42 23 30 0.091
Biological parameters
Albuminb, g/L 37 ± 5 36 ± 5 36 ± 5 37 ± 4 0.396
Hemoglobinb, g/dL 10.0 ± 1.6 10.4 ± 1.5 10.6 ± 1.7 10.6 ± 1.5 0.046
aGroup 1: “intermediate” patients, Group 2: younger patients with severe comorbidities, Group 3: elderly patients with few cardiovascular co-morbidities, Group 4:
patients who initiated cinacalcet; bResults are presented as mean ± SD; cBody mass index; p corresponds to ANOVA.
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http://www.biomedcentral.com/1471-2369/15/132by Pasieka et al. was used in several studies on primary
and secondary hyperparathyroidism to quantify severity
of symptoms using median values [18-20]. In the
EPHEYL study, one out of two patients suffered from at
least one symptom. But the most frequent symptoms
(thirst, weakness, fatigue, and pain of joints) were not
specific. As the questionnaire was developed in the
context of parathyroidectomy, its validity is question-
able at early stage of SHPT.
The PTH cut-off value of 500 ng/L was chosen at the
time of 2003 K-DOQI [6]. Its enabled to focus on SHPT
patients without adynamic bone disease [8,23]. Further-
more, no patient had hypercalcemia, suggesting that
there was no tertiary or autonomized SHPT. This result
is consistent with the incident type of our cohort, as
tertiary SHPT were found in previous studies including
prevalent SHPT patients [6,24]. Nevertheless, we know
that PTH is subject to many simultaneous types of vari-
ability [7,11]. Our study points out obstacles with the
use of PTH to precisely diagnose SHPT. The distribu-
tion of PTH at a cut-off value of 500, according to the
new recommendation: “maintaining PTH levels in the
range of approximately two to nine times the upper
normal limit for the assay” was wide (Figure 2). Jean
et al. have suggested that PTH should be replaced with
specific biochemical markers of bone such as bone ALP
and beta cross-laps to follow-up SHPT [24]. These mea-
surements, however, are too costly to be recommended
in routine clinical practice [8]. Finally, in the context of
quite vague recommendations, clinicians should be aware
that a binary approach for SHPT diagnosis, i.e. absence/
presence, is not adequate. There is definitely a grey zone
for diagnosis which limits are not easily defined. We should
recommend an observation period before acting strongly.
In this grey zone, our study identified four statistically
distinct subgroups of patients. Our description of each
group reflected a clinical reality, and was therefore
clinically appropriate. Noteworthy, at bedside, these
distinct phenotypes should be distinguished by doctor
rather by biological cut-offs. This pleads for patient-
doctor contact. A recent publication has demonstrated
a positive association between patient-doctor contact
and outcomes [25]. Last but not least, our study re-
inforces the recent publication by Levin that has recom-
mended acknowledging the heterogeneity of chronic
kidney disease populations and appropriately characteri-
zing populations for studies [26].
The group of “elderly patients with a few cardio-
vascular comorbidities”, in majority with normocalcemia
and normophosphatemia, had a PTH which, at first,
should impressed clinicians. In another hand, normal
serum phosphorus could not be explained by malnutrition;
despite their old age, nutritional markers (such as albumin
and phosphatemia) were not statistically different fromthose in the other groups. PTH seemed to be associated
with a good clinical condition and a low prevalence of
comorbidities. These results are consistent with those
from previous studies in showing that, particularly in
elderly, PTH is inversely correlated with score of comor-
bidities [12,27]. At the time of diagnosis of SHPT, this sub-
group of patients did not require presumably an intensive
therapeutic management.
The group of “younger patients with severe cardiovas-
cular comorbidities”, by contrast, consisted of a majority
of patients (66%) with PTH within targets [8]. However,
the mean PTH was similar to the one found in the pre-
vious group. They seemed to be most likely to have bone
and cardiovascular complications, as in previous cohorts,
possibly linked to hyperphosphatemia, with a high pro-
portion of cardiovascular diseases, diabetes and obesity
[4,13]. As a result, they should require an intensive care
management. Of note, most of them had hyperphospha-
temia and hypocalcemia despite multiple treatments. It
is obvious that this phenotype is characterized by very
low adherence to first-line strategies for SHPT, e.g.
calcium, vitamin D and phosphorus binders. For this
treatment category, a recent meta-analysis has pointed
out poor adherence in a majority of patients [28].
The group of “intermediate patients” seemed to show
intermediate characteristics between those with both pre-
vious groups. Most of them had hyperphosphatemia with-
out hypocalcemia and the highest PTH. They seemed to
be more likely to be at high risk for cardiovascular events
due to uncontrolled hyperphosphatemia; as a result, they
should be cautiously monitored [21].
Finally, the group of patients “who initiated cinacalcet”
was very different from the others (Figure 3). Most of pa-
tients had hypocalcemia and hyperphosphatemia. Patients
were given already multiple conventional treatments be-
fore cinacalcet initiation. At the time of cinacalcet initi-
ation, an overwhelming majority of patients (86%) had
PTH within KDIGO™ targets which were applicable du-
ring the study period. Our study has confirmed that
cinacalcet was prescribed for broadened indications in
real life, and highlighted that the benefit-risk balance of
cinacalcet was not favorable in patients with low PTH.
This phenotype “cinacalcet user” including such patients
should not exist. Before such therapeutic agents were mar-
keted, indications for surgical parathyroidectomy were
limited to symptomatic SHPT patients with very high
PTH (>1000 ng/L). Initially presented as an alternative to
parathyroidectomy, cinacalcet is now prescribed in pre-
symptomatic patients with PTH > 300 ng/L, perhaps due
to previous KDOQI recommendations.
Its prescription is based on studies suggesting that
cinacalcet should have a protective effect on cardio-
vascular disease outcomes and reduce risk of fractures
[29]. Recently, the prospective EVOLVE study failed to
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vascular mortality and events [10]. These negative re-
sults can be explained, in particular, by the fact that 23%
of patients in the treated group and 11% in the placebo
group received the trade formulation of cinacalcet, which
skewed the results. The EPHEYL study has shown that
the use of cinacalcet was likely to be physician-dependent
rather than characteristic of patients, and decision-making
to prescribe it was insufficiently detailed. Thus in the
group of patients who initiated cinacalcet, 43% of them
who should have been treated with cinacalcet were not
taking treatment 3 months later. Considering that low
PTH levels characterize adynamic bone disease and/or a
high prevalence of comorbidities, we should currently rec-
ommend to prescribe cinacalcet only after conducting a
rigorous investigation on its benefit/risks [23,27]. The
strength of our study was to identify a subgroup of inci-
dent SHPT patients treated with cinacalcet despite low
PTH in a real life setting. The matter whether cinacalcet
should be contraindicated in patients with low PTH is of
great interest.
Our study has some limitations. Its observational nature
which may seem like a drawback is strength actually.
Pharmacoepidemiological study, as EPHEYL, reflects rou-
tine clinical practices with various therapeutic strategies
which are not always consistent with previous randomized
trials [10]. Second, we have taken into account only data
at the inclusion, making sense as regards to the incident
nature of a disease. The 2-year follow-up of the EPHEYL
cohort should reinforce the relevance of the classification.
Third, most of patients were included with a PTH cut-off
value of 500ng/L, while the latest KDIGO™ guidelines have
recommended maintaining PTH in ranges, at approxi-
mately 2 to 9 times the upper normal limit, rather than
absolute values. KDIGO™ recommendations were not
implemented when we wrote our article. As a result, data
on PTH have been detailed in this report. Fourth, the
methodology allowed identification of distinct profiles, not
completely disjunctive. It is therefore possible that some
patients of distinct subgroups should have partially similar
characteristics at junctions. Notwithstanding differences
between groups are relevant. Fifth, clinical symptoms
assessed by PAS questionnaire need to be interpreted with
caution, due to the difficulty met to collect data from
self-administered questionnaire.
Conclusion
In conclusion, four significantly distinct profiles of dia-
lysis patients with a recent severe SHPT diagnosis were
identified on the basis of clinical, biological and thera-
peutic data routinely available. Our well-characterized
incident cohort, coupled with an original methodo-
logical approach, highlights a contemporary picture of
daily clinical practice. Our study reinforces that thebenefit-risk balance of cinacalcet is not positive in
patients with low PTH, and raises the matter whether
cinacalcet should be contraindicated in such patients. A
“one-size-fits-all” target for PTH approach is probably
not appropriate. Therapeutic management needs to be
adjusted to the four different phenotypes.
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